You're using an outdated browser. Please upgrade to a modern browser for the best experience.
Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic. For video creation, please contact our Academic Video Service.
Version Summary Created by Modification Content Size Created at Operation
1 Massimo Franchini + 1618 word(s) 1618 2022-02-15 09:31:26 |
2 format correct Conner Chen -68 word(s) 1550 2022-02-25 01:36:41 | |
3 format correct Conner Chen -68 word(s) 1550 2022-02-25 01:42:02 | |
4 format correct Conner Chen Meta information modification 1550 2022-02-28 07:27:23 |

Video Upload Options

We provide professional Academic Video Service to translate complex research into visually appealing presentations. Would you like to try it?
No, upload directly Yes

Confirm

Are you sure to Delete?
Yes No
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Franchini, M. Biomarkers of Thromboembolic Risk in Atrial Fibrillation. Encyclopedia. Available online: https://encyclopedia.pub/entry/19853 (accessed on 05 December 2025).
Franchini M. Biomarkers of Thromboembolic Risk in Atrial Fibrillation. Encyclopedia. Available at: https://encyclopedia.pub/entry/19853. Accessed December 05, 2025.
Franchini, Massimo. "Biomarkers of Thromboembolic Risk in Atrial Fibrillation" Encyclopedia, https://encyclopedia.pub/entry/19853 (accessed December 05, 2025).
Franchini, M. (2022, February 24). Biomarkers of Thromboembolic Risk in Atrial Fibrillation. In Encyclopedia. https://encyclopedia.pub/entry/19853
Franchini, Massimo. "Biomarkers of Thromboembolic Risk in Atrial Fibrillation." Encyclopedia. Web. 24 February, 2022.
Biomarkers of Thromboembolic Risk in Atrial Fibrillation
Edit
This entry is adapted from the peer-reviewed paper 10.3390/jcm11040915

An ideal biomarker should be simple and practical, have a high sensitivity and be inexpensive. Some clinical markers (e.g., non-paroxysmal type of AF, carotid plaque) and some circulating biomarkers (e.g., cardiac troponin, N-terminal pro-B-type natriuretic protein [BT-proBNP], and D-dimer) are promising for use in IS prediction in patients with NVAF because it is both practical and simple to determine them.

biomarkers atrial fibrillation thromboembolism

1. Clinical Biomarkers

Many of the potential biomarkers are divided into “clinical” and “circulating” [1]. Below is a concise list of potential clinical biomarkers [2].
  • AF characteristics: type, duration, and burden
  • Cardiac imaging:
    1. Left atrial appendage (LAA) morphology, the position of the LAA orifice, LAA flow velocity
    2. Left atrium diameter, atrial fibrosis, left atrial strain
    3. Left ventricle relative wall thickness, left ventricular ejection fraction
    4. Epicardial fat thickness, left atrium spontaneous echo contrast
  • ECG:
    1. P wave terminal force in lead V1
    2. P wave duration
    3. Maximum P wave
    4. Advanced interatrial block
  • Atherosclerosis:
    1. Carotid intima-media thickness
    2. Carotid plaques
    3. Flow-mediated dilation

2. Circulating Biomarkers

2.1. Cardiac Troponins

Troponin is a marker of cardiac necrosis that has been extensively used for decades. It is the most widely used biomarker in cardiovascular disease. Its value in detecting myocardial damage is undisputed, and it can be used to make many important pathophysiological considerations regarding the disease evolution and prognosis
Evidence shows that troponin could be used to predict IS in patients with AF. For example, post-hoc analyses of the clinical trials ARISTOTLE [3], RE-LY [4], and ENGAGE AF-TIMI [5] indicated a positive association between cardiac troponin 1/troponin T levels and the risk of thromboembolism or IS.
V. Roldan et al. demonstrated in a large ‘real-world’ cohort of anticoagulated AF patients that the levels of both high-sensitivity troponin T and high-sensitivity interleukin-6 provided prognostic information that was complementary to that of clinical risk scores for predicting long-term cardiovascular events and death. Therefore, these biomarkers could help to refine risk stratification in AF [6].
A meta-analysis published in 2020 suggested that high-sensitivity cardiac troponin can be considered a biomarker for the risk of incident stroke, with its effect size differing in different subgroups [7].

2.2. BNP and NT-proBNP

B-type natriuretic peptide (BNP) and NT-proBNP are markers of heart failure, secreted in response to increased end-diastolic pressure and/or volume expansion. NT-proBNP results from the enzymatic cleavage of the BNP produced by cardiac myocytes.
Due to atrial dysfunction, their increment may be predictive of higher IS risk [2].
Analyses of the results of the ARISTOTLE [3], RE-LY [4], and ENGAGE AF-TIMI 48 [5] trials demonstrated that NT-proBNP levels were independently associated with an increased risk of IS, and, thus, adding NT-proBNP to the CHA2DS2-VASc score could improve this latter’s predictive power.
In a real-world group of patients with AF receiving anticoagulant treatment, NT-proBNP levels provided complementary prognostic information to the CHA2DS2-VASc score for predicting stroke/systemic embolism. NT-proBNP was also predictive of all-cause mortality. Adding NT-proBNP to the CHA2DS2-VASc score increased the ability of the score to predict the risk of IS/systemic embolism in anticoagulated patients with AF by 17% [8].

2.3. D-Dimer

D-dimer is a degradation product of cross-linked fibrin and a biomarker of activated coagulation and fibrinolysis. Higher levels of D-dimer have been associated with an increased probability of IS [9][10][11][12][13].
A study of 323 patients with NVAF who were not receiving anticoagulation showed that D-dimer level is positively correlated with IS risk stratification but does not have a predictive value for the occurrence of IS in patients with NVAF [14]. Thus, dynamic detection of D-dimer levels might be necessary for patients with NVAF.

2.4. Red Cell Distribution Width

An increased red cell distribution width (RDW) value, due to impaired erythropoiesis, may be associated with thromboembolic events in patients with NVAF and was indeed found to be independently associated with such events in patients with NVAF [15].

2.5. Neutrophil-to-Lymphocyte Ratio

The neutrophil-to-lymphocyte ratio (NLR) is an inexpensive, readily available marker of inflammation. It was associated with an increased risk of long-term mortality in patients admitted to hospital with acute decompensated heart failure, in whom it could be used to aid risk stratification [16]. NLR was also found to be directly associated with stroke risk in a large cohort of AF patients. Adding NLR to the CHA2DS2-VASc score increased the area under the curve from 0.627 (95% confidence interval 0.612–0.643) to 0.635 (0.619–0.651) (p = 0.037) [17].

2.6. Mean Platelet Volume

Mean platelet volume (MPV) indicates the intensity of an inflammatory process and correlates with the risk of thrombotic complications. A study of NVAF patients provided evidence that MPV is an independent predictor of IS in such a population. The combination of the CHA2DS2-VASc score and MPV had a sensitivity of 72.1% for predicting IS and a specificity of 81.5% [18].

2.7. Von Willebrand Factor

Von Willebrand factor (VWF) levels were found to be increased in patients with AF in early studies [19], and in subsequent studies [20][21], they were found to be a predictor of IS and an independent risk factor.

2.8. Plasma Fibrinogen

As noted for VWF, plasma fibrinogen levels were found high in AF patients [22] and positively associated with leukoaraiosis and periventricular hyperintensity in patients with stroke and AF [23].
Prothrombin fragment 1.2 is an index of thrombin generation. It has been demonstrated that thrombin generation increases during AF despite the use of anticoagulants [24]. Though F 1.2 levels and thrombin generation are clearly implicated in the thromboembolic process, their role in predicting or improving the IS risk stratification in AF needs to be investigated more deeply.

2.9. Cholesterol and Lipoproteins

Low-density lipoprotein-cholesterol (LDL-C) was identified as an independent predictor of IS in patients with NVAF in one study [25], but others have not confirmed this result. However, total cholesterol and LDL-C were higher in patients with NVAF who suffered IS than in patients who did not [26].
The ratio of LDL-C to high-density lipoprotein-cholesterol was found to predict IS in a case control study [27] while higher levels of lipoprotein(a) (≥30 mg/dL) seemed to be associated with thromboembolic events [28] although other studies contradict these data.

3. Biomarkers of Inflammation

3.1. C-Reactive Protein

There is considerable evidence that AF is associated with an inflammatory state.
Dernellis et al. [29] described that the occurrence of paroxysmal AF in patients with a high C-reactive protein level is associated with enlargement of the left atrium and depression of left atrial contractile function independently of left ventricular hypertrophy and function.
Lip et al. [30] found that, among AF patients, C-reactive protein level was positively correlated with stroke risk and related to risk factors for stroke and prognosis (mortality, vascular events).

3.2. Uricemia

Hyperuricemia can increase the risk of AF [31]. Numa et al. [32] described that the serum uric acid level was associated with thromboembolic risk on transesophageal echocardiography in patients with NVAF at low-intermediate risk according to stratification by clinical risk factors.

3.3. Soluble CD40L

Soluble CD40L is an 18-KDa trimer that is shed by activated T lymphocytes and platelets and is considered a marker of inflammation and thrombosis in several diseases. Increased levels have been associated with the presence of left atrial thrombus [33] and cerebrovascular events [34].

3.4. Homocysteine

In a series of studies, hyperhomocysteinemia has been found to be independently associated with left atrial thrombus formation in IS patients with NVAF and with a history of IS in NVAF patients hospitalized for cardiac reasons [35][36].

3.5. GDF-15, TMAO, IL-1ra, IL-6

Growth differentiation factor-15 (GDF-15) is a transforming growth factor beta superfamily member. Physiologically, GDF-15, a peptide hormone, is expressed at low concentrations in numerous tissues. GDF-15 is overexpressed during and after many pathological conditions, including tissue injury and inflammation, in order to exert a protective function. Elevated GDF-15 levels may indicate a significantly increased risk of left atrial/LAA thrombus in NVAF patients. They could, therefore, potentially be a useful adjunct in discriminating left atrial/LAA thrombus in such patients [37].
Trimethylamine N-oxide (TMAO) is a small amine oxide that is generated by the microbial metabolism of choline, betaine, and carnitine in the gut. There is a report of a positive correlation between elevated plasma levels of TMAO and an increased risk of major adverse cardiovascular events and death. In a recent work [38], univariate and multivariate logistic regression analyses indicated that TMAO was an independent predictor in IS. The level of TMAO was correlated with the CHA2DS2-VASc score. Since TMAO is thought to be an independent predictor of IS, it could potentially refine stroke stratification in patients with AF.
The causal role of interleukins in the pathogenesis of vascular diseases has not been fully elucidated. However, a recent article [39] described an inverse relationship of interleukin-6 and a direct one of interleukin-1 receptor antagonist with cardio-embolic stroke.

4. Other Biomarkers

4.1. Galectin-3

Galectin-3, a lectin that binds β-galactosides, is involved in cardiac remodeling and fibrosis through its effect of activating macrophages and fibroblasts. Various studies have documented that increased levels of circulating galectin-3 are associated with AF-related IS and LAA thrombus formation [40][41].

4.2. ST-2

Suppression of tumorigenicity 2 (ST2) is a member of the interleukin-1 receptor family and circulating soluble ST2 concentrations have been suggested to be a biomarker of cardiovascular stress and fibrosis and were independently and significantly related to AF recurrence in patients with NVAF [42].

4.3. Protein Biomarker Discovery Platforms

Protein concentrations in blood are more closely linked to disease phenotype than any other biomarker in blood. New protein biomarker discovery platforms as Olink Explore or SomaLogic that can sustain high throughput, though maintaining the performance of the “state of the art” manual methods, can be successfully used to investigate the continuously evolving field of circulating biomarkers and their practical applications [1].

References

  1. Shang, L.; Zhang, L.; Guo, Y.; Sun, H.; Zhang, X.; Bo, Y.; Zhou, X.; Tang, B. A Review of Biomarkers for Ischemic Stroke Evaluation in Patients with Non-valvular Atrial Fibrillation. Front. Cardiovasc. Med. 2021, 8, 682538.
  2. Hijazi, Z.; Oldgren, J.; Siegbahn, A.; Granger, C.B.; Wallentin, L. Biomarkers in atrial fibrillation: A clinical review. Eur. Heart J. 2013, 34, 1475–1480.
  3. Hijazi, Z.; Wallentin, L.; Siegbahn, A.; Andersson, U.; Christersson, C.; Ezekowitz, J.; Gersh, B.J.; Hanna, M.; Hohnloser, S.; Horowitz, J.; et al. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: Insights from the ARISTOTLE trial (Apixaban for the Prevention of Stroke in Subjects with Atrial Fibrillation). J. Am. Coll. Cardiol. 2013, 61, 2274–2284.
  4. Hijazi, Z.; Oldgren, J.; Andersson, U.; Connolly, S.J.; Ezekowitz, M.D.; Hohnloser, S.H.; Reilly, P.A.; Vinereanu, D.; Siegbahn, A.; Yusuf, S.; et al. Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation: A Randomized Evaluation of Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012, 125, 1605–1616.
  5. Ruff, C.T.; Giugliano, R.P.; Braunwald, E.; Murphy, S.A.; Brown, K.; Jarolim, P.; Mercuri, M.; Antman, E.M.; Morrow, D.A. Cardiovascular biomarker score and clinical outcomes in patients with atrial fibrillation: A subanalysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol. 2016, 1, 999–1006.
  6. Roldán, V.; Marín, F.; Díaz, J.; Gallego, P.; Jover, E.; Romera, M.; Manzano-Fernández, S.; Casas, T.; Valdés, M.; Vicente, V.; et al. High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. J. Thromb. Haemost. 2012, 10, 1500–1507.
  7. Broersen, L.H.A.; Stengl, H.; Nolte, C.H.; Westermann, D.; Endres, M.; Siegerink, B.; Scheitz, J.F. Association between high-sensitivity cardiac troponin and risk of stroke in 96 702 individuals: A meta-analysis. Stroke 2020, 51, 1085–1093.
  8. Roldán, V.; Vílchez, J.A.; Manzano-Fernández, S.; Jover, E.; Gálvez, J.; Puche, C.M.; Valdés, M.; Vicente, V.; Lip, G.Y.; Marin, F. Usefulness of N-terminal pro-B-type natriuretic Peptide levels for stroke risk prediction in anticoagulated patients with atrial fibrillation. Stroke 2014, 45, 696–701.
  9. Kim, T.W.; Song, I.U.; Chung, S.W.; Kim, J.S.; Koo, J.; Lee, K.S. Serum D-dimer levels are proportionally associated with left atrial enlargement in patients with an acute ischemic stroke due to non-valvular atrial fibrillation. Intern. Med. 2016, 55, 1447–1452.
  10. Christersson, C.; Wallentin, L.; Andersson, U.; Alexander, J.H.; Ansell, J.; De Caterina, R.; Gersh, B.J.; Granger, C.B.; Hanna, M.; Horowitz, J.; et al. D-dimer and risk of thromboembolic and bleeding events in patients with atrial fibrillation–observations from the ARISTOTLE trial. J. Thromb. Haemost. 2014, 12, 1401–1412.
  11. Mahé, I.; Bergmann, J.F.; Chassany, O.; dit-Sollier, C.B.; Simoneau, G.; Drouet, L. A multicentric prospective study in usual care: D-dimer and cardiovascular events in patients with atrial fibrillation. Thromb. Res. 2012, 129, 693–699.
  12. Nozawa, T.; Inoue, H.; Hirai, T.; Iwasa, A.; Okumura, K.; Lee, J.D.; Shimizu, A.; Hayano, M.; Yano, K. D-dimer level influences thromboembolic events in patients with atrial fibrillation. Int. J. Cardiol. 2006, 109, 59–65.
  13. Siegbahn, A.; Oldgren, J.; Andersson, U.; Ezekowitz, M.D.; Reilly, P.A.; Connolly, S.J.; Yusuf, S.; Wallentin, L.; Eikelboom, J.W.; Siegbahn, A. D-dimer and factor VIIa in atrial fibrillation—Prognostic values for cardiovascular events and effects of anticoagulation therapy. A RE-LY substudy. Thromb. Haemost. 2016, 115, 921–930.
  14. You, L.R.; Tang, M. The association of high D-dimer level with high risk of ischemic stroke in nonvalvular atrial fibrillation patients: A retrospective study. Medicine 2018, 97, e12622.
  15. Cha, M.J.; Lee, H.S.; Kim, H.M.; Jung, J.H.; Choi, E.K.; Oh, S. Association between red cell distribution width and thromboembolic events in patients with atrial fibrillation. Eur. J. Intern. Med. 2017, 46, 41–46.
  16. Uthamalingam, S.; Patvardhan, E.A.; Subramanian, S.; Ahmed, W.; Martin, W.; Daley, M.; Capodilupo, R. Utility of the neutrophil to lymphocyte ratio in predicting long-term outcomes in acute decompensated heart failure. Am. J. Cardiol. 2011, 107, 433–438.
  17. Saliba, W.; Barnett-Griness, O.; Elias, M.; Rennert, G. Neutrophil to lymphocyte ratio and risk of a first episode of stroke in patients with atrial fibrillation: A cohort study. J. Thromb. Haemost. 2015, 13, 1971–1979.
  18. Zheng, M.; Chen, S.; Zhu, Y.; Gu, X. Mean platelet volume: A new predictor of ischaemic stroke risk in patients with nonvalvular atrial fibrillation. BMC Cardiovasc. Disord. 2020, 20, 241.
  19. Lip, G.Y.; Lowe, G.D.; Rumley, A.; Dunn, F.G. Increased markers of thrombogenesis in chronic atrial fibrillation: Effects of warfarin treatment. Br. Heart J. 1995, 73, 527–533.
  20. Ancedy, Y.; Berthelot, E.; Lang, S.; Ederhy, S.; Boyer-Chatenet, L.; Di Angelantonio, E.; Dufour, L.S.; Etienney, A.; Adavane-Scheublé, S.; Boccara, F.; et al. Is von Willebrand factor associated with stroke and death at midterm in patients with non-valvular atrial fibrillation? Arch. Cardiovasc. Dis. 2018, 111, 357–369.
  21. Pinto, A.; Tuttolomondo, A.; Casuccio, A.; Di Raimondo, D.; Di Sciacca, R.; Arnao, V.; Licata, G. Immuno-inflammatory predictors of stroke at follow-up in patients with chronic non-valvular atrial fibrillation (NVAF). Clin. Sci. 2009, 116, 781–789.
  22. Weymann, A.; Sabashnikov, A.; Ali-Hasan-Al-Saegh, S.; Popov, A.F.; Jalil Mirhosseini, S.; Baker, W.L.; Lotfaliani, M.; Liu, T.; Dehghan, H.; Yavuz, S.; et al. Predictive role of coagulation, fibrinolytic, and endothelial markers in patients with atrial fibrillation, stroke, and thromboembolism: A meta-analysis, meta-regression, systematic review. Med. Sci. Monit. Basic Res. 2017, 23, 97–140.
  23. Wei, C.C.; Zhang, S.T.; Liu, J.F.; Lin, J.; Yang, T.T.; Zhang, S.H.; Liu, M. Association between fibrinogen and leukoaraiosis in patients with ischemic stroke and atrial fibrillation. J. Stroke Cereb. Dis. 2017, 26, 2630–2637.
  24. Liles, J.; Liles, J.; Wanderling, C.; Syed, M.; Hoppensteadt, D.; Fareed, J. Increased Level of Thrombotic Biomarkers in Patients with Atrial Fibrillation Despite Traditional and New Anticoagulant Therapy. Clin. Appl. Thromb. Hemost. Novemb. 2016, 22, 743–748.
  25. Qi, Z.; Chen, H.; Wen, Z.; Yuan, F.; Ni, H.; Gao, W.; Shen, J.; Li, J.; Lin, Y.; Shan, Y.; et al. Relation of low-density lipoprotein cholesterol to ischemic stroke in patients with nonvalvular atrial fibrillation. Am. J. Cardiol. 2017, 119, 1224–1228.
  26. Li, W.; Zeng, X.; Xu, L.; Wang, T.; Lin, W.; Li, Y.; Luo, Y.; Luo, B. Optimized stratification of risk factors in and beyond the CHA 2 DS 2 -VASc score to differentiate the real thromboembolic risk in mainland China: A systematic review and meta-analysis. Ann. Palliat. Med. 2020, 9, 4252–4261.
  27. Zhang, X.X.; Wei, M.; Shang, L.X.; Lu, Y.M.; Zhang, L.; Li, Y.D.; Zhang, J.-H.; Xing, Q.; Tu-Erhong, Z.K.; Tang, B.-P.; et al. LDLC/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: A case-control study. Lipids Health Dis. 2020, 19, 217.
  28. Okura, H.; Inoue, H.; Tomon, M.; Nishiyama, S.; Yoshikawa, T. Increased plasma lipoprotein(a) level in cardioembolic stroke with non-valvular atrial fibrillation. Intern. Med. 1998, 37, 995.
  29. Dernellis, J.; Panaretou, M. Left atrial function in patients with a high Creactive protein level and paroxysmal atrial fibrillation. Acta Cardiol. 2006, 61, 507–511.
  30. Lip, G.Y.; Patel, J.V.; Hughes, E.; Hart, R.G. High-sensitivity C-reactive protein and soluble CD40 ligand as indices of inflammation and platelet activation in 880 patients with nonvalvular atrial fibrillation: Relationship to stroke risk factors, stroke risk stratification schema, and prognosis. Stroke 2007, 38, 1229–1237.
  31. Zhang, J.; Zheng, R.; Li, H.; Guo, J. Serumuric acid and incident atrial fibrillation: A systematic review and dose-response meta-analysis. Clin. Exp. Pharmacol. Physiol. 2020, 47, 1774–1782.
  32. Numa, S.; Hirai, T.; Nakagawa, K.; Ohara, K.; Fukuda, N.; Nozawa, T.; Inoue, H. Hyperuricemia and transesophageal echocardiographic thromboembolic risk in patients with atrial fibrillation at clinically low-intermediate risk. Circ. J. 2014, 78, 1600–1605.
  33. Tarnowski, D.; Poitz, D.M.; Plichta, L.; Heidrich, F.M.; Wiedemann, S.; Ruf, T.; Mierke, J.; Löhn, T.; Jellinghaus, S.; Strasser, R.H.; et al. Comparison of diverse platelet activation markers as indicators for left atrial thrombus in atrial fibrillation. Platelets 2018, 29, 41–47.
  34. Duygu, H.; Barisik, V.; Kurt, H.; Turk, U.; Ercan, E.; Kose, S. Prognostic value of plasma soluble CD40 ligand in patients with chronic non-valvular atrial fibrillation. Europace 2008, 10, 210–214.
  35. Ay, H.; Arsava, E.M.; Tokgözoglu, S.L.; Ozer, N.; Saribas, O. Hyperhomocysteinemia is associated with the presence of left atrial thrombus in stroke patients with nonvalvular atrial fibrillation. Stroke 2003, 34, 909–912.
  36. Loffredo, L.; Violi, F.; Fimognari, F.L.; Cangemi, R.; Sbrighi, P.S.; Sampietro, F.; Mazzola, G.; Di Lecce, V.N.; D’Angelo, A. The association between hyperhomocysteinemia and ischemic stroke in patients with non-valvular atrial fibrillation. Haematologica 2005, 90, 1205–1211.
  37. Hu, X.F.; Zhan, R.; Xu, S.; Wang, J.; Wu, J.; Liu, X.; Chen, L. Growth differentiation factor 15 is associated with left atrial/left atrial appendage thrombus in patients with nonvalvular atrial fibrillation. Clin. Cardiol. 2018, 41, 34–38.
  38. Liang, Z.; Dong, Z.; Guo, M.; Shen, Z.; Yin, D.; Hu, S.; Hai, X. Trimethylamine Noxide as a risk marker for ischemic stroke in patients with atrial fibrillation. J. Biochem. Mol. Toxicol. 2019, 33, e22246.
  39. Yuan, S.; Lin, A.; He, Q.Q.; Burgess, S.; Larsson, S.C. Circulating interleukins in relation to coronary artery disease, atrial fibrillation and ischemic stroke and its subtypes: A two-sample Mendelian randomization study. Int. J. Cardiol. 2020, 313, 99–104.
  40. Merino-Merino, A.; Gonzalez-Bernal, J.; Fernandez-Zoppino, D.; Saez-Maleta, R.; Perez-Rivera, J.-A. The Role of Galectin-3 and ST2 in Cardiology: A Short Review. Biomolecules 2021, 11, 1167.
  41. Tang, Z.; Zeng, L.; Lin, Y.; Han, Z.; Gu, J.; Wang, C.; Zhang, H. Circulating Galectin-3 is associated with left atrial appendage remodelling and thrombus formation in patients with atrial fibrillation. Heart Lung Circ. 2019, 28, 923–931.
  42. Okar, S.; Kaypakli, O.; Sahin, D.Y.; Koc, M. Fibrosis Marker Soluble ST2 Predicts Atrial Fibrillation Recurrence after Cryoballoon Catheter Ablation of Nonvalvular Paroxysmal Atrial Fibrillation. Korean Circ. J. 2018, 48, 920–929.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
Upload a video for this entry
Information
Subjects: Hematology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : Massimo Franchini
View Times: 983
Entry Collection: Hypertension and Cardiovascular Diseases
Revisions: 4 times (View History)
Update Date: 28 Feb 2022
Table of Contents
    1000/1000
    Hot Most Recent
    Notice
    You are not a member of the advisory board for this topic. If you want to update advisory board member profile, please contact office@encyclopedia.pub.
    OK
    Confirm
    Only members of the Encyclopedia advisory board for this topic are allowed to note entries. Would you like to become an advisory board member of the Encyclopedia?
    Yes
    No
    Academic Video Service
    Feedback